These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 34025442)
1. Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling. Chen T; Ni N; Yuan L; Xu L; Bahri N; Sun B; Wu Y; Ou WB Front Pharmacol; 2021; 12():686874. PubMed ID: 34025442 [No Abstract] [Full Text] [Related]
2. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Ou WB; Ni N; Zuo R; Zhuang W; Zhu M; Kyriazoglou A; Wu D; Eilers G; Demetri GD; Qiu H; Li B; Marino-Enriquez A; Fletcher JA Oncogene; 2019 Sep; 38(39):6615-6629. PubMed ID: 31371779 [TBL] [Abstract][Full Text] [Related]
3. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. Tu Y; Zuo R; Ni N; Eilers G; Wu D; Pei Y; Nie Z; Wu Y; Wu Y; Ou WB Cell Cycle; 2018; 17(23):2577-2592. PubMed ID: 30488756 [TBL] [Abstract][Full Text] [Related]
4. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors. Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells. Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303 [TBL] [Abstract][Full Text] [Related]
6. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S; Duensing A; Demetri GD; Fletcher JA Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049 [TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
8. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Rausch JL; Ali AA; Lee DM; Gebreyohannes YK; Mehalek KR; Agha A; Patil SS; Tolstov Y; Wellens J; Dhillon HS; Makielski KR; Debiec-Rychter M; Schöffski P; Wozniak A; Duensing A Sci Rep; 2020 Mar; 10(1):5178. PubMed ID: 32198455 [TBL] [Abstract][Full Text] [Related]
9. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Sabah M; Cummins R; Leader M; Kay E Hum Pathol; 2006 Jun; 37(6):648-55. PubMed ID: 16733203 [TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
11. YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Ou WB; Lundberg MZ; Zhu S; Bahri N; Kyriazoglou A; Xu L; Chen T; Mariño-Enriquez A; Fletcher JA Oncogenesis; 2021 May; 10(5):37. PubMed ID: 33947829 [TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Bauer S; Yu LK; Demetri GD; Fletcher JA Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758 [TBL] [Abstract][Full Text] [Related]
15. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. Yun S; Kim WK; Kwon Y; Jang M; Bauer S; Kim H Int J Cancer; 2018 May; 142(10):2080-2093. PubMed ID: 29277888 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Duensing A; Medeiros F; McConarty B; Joseph NE; Panigrahy D; Singer S; Fletcher CD; Demetri GD; Fletcher JA Oncogene; 2004 May; 23(22):3999-4006. PubMed ID: 15007386 [TBL] [Abstract][Full Text] [Related]
17. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589 [TBL] [Abstract][Full Text] [Related]
19. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460 [TBL] [Abstract][Full Text] [Related]
20. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]